These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8222252)

  • 1. Circadian pharmacodynamics of anticancer therapies.
    Hrushesky WJ
    Clin Chem; 1993 Nov; 39(11 Pt 2):2413-8. PubMed ID: 8222252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer chronotherapy: is there a right time in the day to treat?
    Hrushesky WJ
    J Infus Chemother; 1995; 5(1):38-43. PubMed ID: 7634176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circadian cancer therapy.
    Hrushesky WJ; Bjarnason GA
    J Clin Oncol; 1993 Jul; 11(7):1403-17. PubMed ID: 8315438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical basis for circadian-dependent metabolism of fluoropyrimidines.
    Daher GC; Harris BE; Willard EM; Diasio RB
    Ann N Y Acad Sci; 1991; 618():350-61. PubMed ID: 1826077
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical cancer chronotherapy trials: a review.
    Bjarnason GA
    J Infus Chemother; 1995; 5(1):31-7. PubMed ID: 7634175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More evidence for circadian rhythm effects in cancer chemotherapy: the fluoropyrimidine story.
    Hrushesky WJ
    Cancer Cells; 1990 Mar; 2(3):65-8. PubMed ID: 2143918
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer chronotherapy: a drug delivery challenge.
    Hrushesky WJ
    Prog Clin Biol Res; 1990; 341A():1-10. PubMed ID: 2145583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic aspects of arterial fluoropyrimidine delivery.
    Collins JM
    Ann N Y Acad Sci; 1991; 618():345-9. PubMed ID: 1826076
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer.
    Kelsen DP; Saltz L; Cohen AM; Yao TJ; Enker W; Tong W; Tao Y; Bertino JR
    Cancer; 1994 Oct; 74(8):2224-33. PubMed ID: 7922973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
    Fleming GF; Schumm P; Friberg G; Ratain MJ; Njiaju UO; Schilsky RL
    BMC Cancer; 2015 Feb; 15():69. PubMed ID: 25885822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Potentialities of fluorine-19 and phosphorus-31 NMR for studying the metabolism and pharmacokinetics of fluorinated or phosphoric antineoplastic agents].
    Martino R; Malet-Martino MC; Armand JP; De Forni M
    Bull Cancer; 1989; 76(8):859-61. PubMed ID: 2533514
    [No Abstract]   [Full Text] [Related]  

  • 12. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling.
    Altinok A; Lévi F; Goldbeter A
    Eur J Pharm Sci; 2009 Jan; 36(1):20-38. PubMed ID: 19041394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes!
    Kemeny NE
    Important Adv Oncol; 1992; ():207-27. PubMed ID: 1533847
    [No Abstract]   [Full Text] [Related]  

  • 14. [Doxifluridine toxicity, a fluorouracil analog with low myelosuppressive effect].
    Winkelmann JJ; Alberto P; Mermillod B
    Bull Cancer; 1990; 77(3):225-34. PubMed ID: 2140280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The study of 5-FU levels and pyrimidine nucleoside phosphorylase (PyNPase) activity in human breast cancer tissue after administration of 5'-deoxy-5-fluorouridine (5'-DFUR)].
    Yayoi E; Takatsuka Y; Miyauchi K; Hirai T; Aikawa T; Maeura Y; Kaji M; Kitada M; Kotsuma Y; Satomi T
    Gan To Kagaku Ryoho; 1990 Jul; 17(7):1371-4. PubMed ID: 2142401
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil.
    Derissen EJ; Hillebrand MJ; Rosing H; Schellens JH; Beijnen JH
    J Pharm Biomed Anal; 2015 Jun; 110():58-66. PubMed ID: 25804433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological perspectives on circadian cancer therapy.
    Wood PA; Hrushesky WJ
    J Infus Chemother; 1995; 5(4):182-90. PubMed ID: 8934723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man.
    Powis G
    Drug Metab Rev; 1983; 14(6):1145-63. PubMed ID: 6373208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A study of preoperative administration of 5'-DFUR in patients with colo-rectal cancer].
    Haruta A; Umeno T; Tanaka S; Toriya H; Jyozaki H; Ikeda S
    Gan To Kagaku Ryoho; 1994 Oct; 21(14):2427-30. PubMed ID: 7944487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the pharmacokinetics of 5'-deoxy-5-fluorouridine and 5-fluorouracil in rats by oral co-administration of acyclothymidine.
    Hamada A; Fukushima S; Saneyoshi M; Shimizu S; Kawaguchi T; Nakano M
    Biol Pharm Bull; 1996 May; 19(5):729-32. PubMed ID: 8741584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.